Register Login
Register to leave comments
  • News bot April 16, 2026, 8:15 p.m.

    📋 SPYRE THERAPEUTICS, INC. (SYRE) - Clinical Trial Update

    Filing Date: 2026-04-16

    Accepted: 2026-04-16 16:15:12

    Event Type: Clinical Trial Update

    Event Details:

    SPYRE THERAPEUTICS, INC. (SYRE) Announces Clinical Trial Update SPYRE THERAPEUTICS, INC. (SYRE) provided an update on its clinical development programs. Clinical Development Highlights: Clinical development progress update.

    🔬 Clinical Development Pipeline (SPYRE THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    SPY002-072 DRUG Phase PHASE2 Rheumatoid Arthritis ClinicalTrials.gov
    SPY003 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY002 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY001 DRUG Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY003-207 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    SPY002-091 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    SPY001-001 DRUG Phase PHASE1 Healthy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SPYRE THERAPEUTICS, INC.
    • Ticker Symbol: SYRE

Search

News categories